EMPLOYMENT AGREEMENT
EXHIBIT 10.(w.1)
EMPLOYMENT AGREEMENT
This Agreement (Agreement) made as of February 14, 2000, between DUSA Pharmaceuticals, Inc., a New Jersey corporation (the Corporation) and Mark Carota, (Carota), who resides at 144 Old Westford Road, Chelmsford, Massachusetts 01824:
NOW, THEREFORE, in consideration of the covenants and promises contained herein and in accordance with the terms and conditions set forth in this Agreement, the parties mutually agree as follows:
1. Employment: The Corporation hereby employs Carota and he hereby accepts such employment as the Vice President - Operations of the Corporation. Carota agrees to devote his full time and best efforts to manage all activities relating to the manufacturing operations of the drugs and devices products of the Corporation in a cost effective and regulatory compliant manner. Carota shall supervise and coordinate manufacturing activities, whether at facilities of the Corporation or at third-party manufacturers. Carota shall report to the Chief Operating Officer of the Corporation as determined by the Corporations board of directors.
2. Duties and Responsibilities: Notwithstanding any language contained herein to the contrary, Carotas responsibilities (by way of example and not by way of limitation) shall include:
A. Supervision and oversight of staff and operations regarding the manufacturing of drugs and devices to support clinical activities or for post-regulatory approval supplies;
B. Management of operational budgets and production functions to meet demand for the Corporations products and to maintain cost objectives relating to cost of goods;
C. Management of Quality Control and Quality Assurance activities of the Corporation in compliance with GMP/QSR regulations and customer requirements;
D. Supervision and hiring of management, technical, and administrative personnel as authorized in the budget, from time, to time;
E. Any additional responsibilities assigned by the Chief Operating Officer or Chief Executive Officer, from time to time.
3. Remuneration: The Corporation shall pay to Carota an initial base salary equal to $140,000 per annum at intervals consistent with the Corporations administrative practices, from time to time. His base salary shall be reviewed by the Board, from time to time, not less than on an annual basis, beginning in January, 2001. Any salary increases shall be determined by, and shall be made at the sole discretion of the Board. Following the end of each fiscal year, the Board may award a cash bonus to Carota in an amount up to 30% of Carotas current base salary for such year, as determined by the Board in its sole discretion. For purposes of awarding the total amount of such bonus, mutually agreeable performance objectives will be set at the beginning of any calendar year during Carotas employment. The Board may award annual cash bonuses above 30% of then current base salary for outstanding performance.
All salary and other payments and allowances outlined in this Agreement shall be subject to such withholding taxes and deductions as may be required by law.
4. Place of Employment: As Vice President - Operations, Carota shall operate from the offices currently located in Wilmington, Massachusetts. Carota acknowledges, however, that there will be domestic and international travel required on a regular basis. Such travel is understood to be necessary in order to effectively conduct his responsibilities for the Corporation.
5. Benefits: Carota will be entitled to participate in the medical, disability, life, and other insurance benefit plans or pension, profit sharing, or 401K plans which may be made available to the officers and employees of the Corporation from time to time, subject to applicable eligibility rules thereof.
6. Stock Options: As an incentive to Carota to continue in the employment with the Corporation, the Corporation hereby agrees to grant to Carota incentive stock options to purchase up to 10,000 shares of the Corporations common stock at the closing price of the common stock on NASDAQ on the date of grant, pursuant to the Corporations 1996 Omnibus Plan, as amended. These options will vest at the rate of twenty-five percent (25%) per year over four (4) years, commencing on the date hereof, and will have a term of ten (10) years. Thereafter, Carota shall be entitled to participate in the 1996 Omnibus Plan, and any subsequent stock purchase and bonus or incentive plans that the Corporation shall from time to time make available to its officers and employees, subject to applicable eligibility rules thereof.
7. Other Allowances: The Corporation shall provide on-line access to the Corporations LAN system for Carotas use at his residence.
8. Vacation: Carota shall be entitled to four (4) weeks of vacation during each year of employment, to be taken at a time or times acceptable to the Corporation, having regard to its operations. Carota shall not be entitled to carry over any unused vacation from one (1) calendar year into the following calendar year, so long as such a vacation policy is consistent for all employees.
9. Expenses: All reasonable travel and other expenses incident to the rendering of services by Carota on behalf of and in promoting the interests of the Corporation shall be paid by the Corporation. If such expenses are paid in the first instance by Carota, the Corporation agrees that it will reimburse Carota therefor upon presentation of appropriate statements, vouchers, bills and invoices as and when required by the Corporation to support the reimbursement request.
10. Confidential Information:
A. Carota understands that in the performance of his services hereunder he may obtain knowledge of confidential information, as hereinafter defined, relating to the business of the Corporation. As used herein, confidential information means any information (whether clinical, financial, administrative or otherwise), written or oral, (including without limitation, any formula, pattern, device, plan, process, or compilation of information) which (i) is, or is designed to be, used in the business of the Corporation or results from its research and/or development activities, or (ii) is private or confidential in that it is not generally known or available to the public, or (iii) gives the Corporation an opportunity to obtain an advantage over competitors who do not know or use it. Carota shall not, without the written consent of the Board, either during the term of his employment or thereafter, (a) use or disclose any such confidential information outside of the Corporation (except to consultants or other agents or representatives of the Corporation who are similarly bound to the Corporation by confidentiality obligations), (b) publish any article with respect thereto, (c) except in the performance of his services hereunder, remove or aid in the removal from the premises of the Corporation any such confidential information or any property or material which relates thereto.
B. Upon the termination of his employment with the Corporation, all documents, records, notebooks and similar repositories of or continuing information concerning the Corporation, or its products, services or customers, including any copies thereof, then in Carotas possession or under his control, whether prepared by Carota or others, will be left with or immediately returned to the Corporation by Carota.
C. (i) Carota shall promptly disclose to the Corporation any and all prescription drug products, devices, machines, methods, inventions, discoveries, improvements, processes, works or the like (all of which are referred to herein as inventions) which he may invent, conceive, produce, or reduce to practice, either solely or jointly with others, at any time (whether or not during work hours) during his employment hereunder.
(ii) All such inventions which in any way relate to the products manufactured, sold or used by the Corporation or to any methods, processes or apparatus used in connection with the manufacture of such products or treatment of disease or conditions, or in either case which are or may be or may become capable of
use in the business of the Corporation, shall at all times and for all purposes be regarded as acquired and held by Carota in a fiduciary capacity for, solely for the benefit of, the Corporation.
(iii) With respect to all such inventions, Carota shall:
(a) treat all information with respect thereto as confidential information within the meaning of, and subject to paragraph 9 above;
(b) keep complete and accurate records thereof, which records shall be the property of the Corporation;
(c) execute any application for letters patent of the United States and of any and all other countries covering such inventions, and give to the Corporation, its attorneys and solicitors all reasonable and requested assistance in preparing such application;
(d) from time to time, upon the request and at the expense of the Corporation, but without charge for services beyond the salary paid to him by the Corporation, execute all assignment or other instruments required to transfer and assign to the Corporation (or as it may direct) all inventions, and all patents and applications for patents, copyrights or applications for registration of copyrights, covering such inventions or otherwise required to protect the rights and interests of the Corporation;
(e) testify in any proceedings or litigation as to all such inventions; and
(f) in case the Corporation shall desire to keep secret any such invention, or shall for any reason decide not to have letters patent applied for thereon, refrain from applying for letters patent thereon.
D. Notwithstanding any of the foregoing in this section, information, whether confidential or proprietary or not, shall be exempt from the above confidentiality provisions if said information:
(i) is known to Carota prior to his employment or consultancy with the Corporation;
(ii) is in the public domain on the date of employment;
(iii) becomes public at any time through no fault of Carota; or
(iv) is or becomes readily available from third parties who have no confidentiality obligations to the Corporation.
E. Carota shall not, without the express prior written consent of the Corporation, directly, or indirectly, during the term of this Agreement or for a period of one (1) year after its termination, render services, or engage in activity including but not limited to, the activities enumerated in Section 2 hereof or any similar activity, for any company which would lead to the development of photodynamic therapy or photodetection products directly competitive (i.e., medically or therapeutically) with the Corporations products or compounds or mixtures thereof, whether alone or as a partner, officer, director, employee or shareholder of any other corporation, or as a trustee, fiduciary, consultant or other representative of any other activity. This restriction shall not apply if Carota has disclosed to the Corporation, in writing, all the known facts relating to such work or activity and has received a release, in writing from the Corporation, to engage in such work or activity. The making of passive and personal investments and the conduct of private business affairs shall not be prohibited hereunder. Ownership by Carota of five percent (5%) or less of the outstanding shares of stock of any corporation either (i) listed on a national securities exchange or (ii) having at least 100 stockholders shall not make Carota a stockholder within the meaning of that term as used in this paragraph, so long as Carota has no participation in the management of such corporation.
11. Termination of Employment:
A. The Corporation may terminate this Agreement at any time, with or without cause on sixty (60) days prior written notice. For purposes of this Agreement, cause shall mean (i) Carotas physical or mental disability or other inability to perform the duties of his job for any reason for a period in excess of six (6) consecutive months, (ii) Carotas conviction in a court of law of a crime or offense, which conviction would prevent Carota from effective management of the Company or materially adversely affect the reputation of the Company, as determined by the Board in its sole discretion, exercising its reasonable judgment, or (iii) Carotas malfeasance or misconduct such as fraud, embezzlement, dishonesty, acts of moral turpitude, or a felony conviction, or for other good cause materially detrimental to DUSA. In the event of a termination for cause, Carota shall be paid his base salary, pro rated to the date of termination. Nothing contained herein shall be interpreted to impair or otherwise affect the right of the Corporation to terminate Carotas employment, at will, with or without good cause.
B. If Carotas employment is terminated by the Corporation without cause, the Corporation shall:
(i) pay Carota a severance allowance equivalent to twelve (12) months then current base salary, payable as a lump sum, within sixty (60) days following the date of such termination;
(ii) pay to Carota within two (2) weeks of the date of termination all outstanding vacation pay and any earned but unpaid salary or bonuses to the
date of such termination and reimburse Carota for any business expense incurred by him up to and including the date of such termination following provision by Carota of all applicable and necessary receipts.
C. Termination upon Death: Carotas employment with the Corporation will cease and this Agreement will terminate without further compensation if Carota dies. Upon his death, his estate will be entitled to any Corporation paid death benefit in force at the time of such death. In addition, Carotas estate shall be paid any cash bonus to which he would have been entitled under Paragraph 3 above. Likewise, Carotas beneficiaries as designated by him to the Corporation shall be entitled to receive the benefits, if any, described in Paragraphs 5 and 6 above, and will be entitled to exercise any vested but unexercised stock options that were held by him at the time of his death, subject to the terms and conditions of such options.
D. Resignation: Carota will provide the Corporation with two (2) months advance notice, in writing, of his resignation from the Corporation.
12. Indemnification: The Corporation shall, to the extent permitted by the laws of the State of New Jersey, indemnify Carota against any actual or threatened action, suit or proceeding, whether civil, criminal, administrative or investigative, that arises as a consequence of his duties as an employer and officer of the Corporation. Such indemnification will include such expenses as attorneys fees, judgments, fines and amounts awarded or agreed to in settlement, provided that Carota acted legally and in good faith, or reasonably believed that his actions were legal and performed in good faith. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendre shall not, of itself, create a presumption that his actions were illegal or not performed in good faith.
13. Representation Concerning Prior Employment: Carota represents and warrants to the Corporation that none of the duties or obligations for which he is responsible under this Agreement breaches, or will cause him to breach in the future, any restrictive covenant or confidentiality obligation under any former employment agreement.
14. Provisions Operating Following Termination: Notwithstanding any termination of Carotas employment with or without cause, any provision of this Agreement necessary to give it efficacy shall continue in full force and effect following such termination.
15. Notices: Any notice to be given in connection with this Agreement shall be given in writing and may be given by personal delivery, by certified mail, postage prepaid, or by facsimile transmission, so long as receipt of such transmission is available, addressed to the recipient as follows:
To: Mark Carota
144 Old Westford Rd.
Chelmsford, MA 01824
To: Ronald L. Carroll
DUSA Pharmaceuticals, Inc.
25 Upton Drive
Wilmington, MA 01887
or to such other address or individual as may be designated by notice by either party to the other. Any notice given by personal delivery shall be deemed to have been given on the day of actual delivery and, if made or given by certified mail, on the third day, other than a Saturday, Sunday, or a statutory holiday in Toronto, Ontario, CANADA following the deposit thereof with the U.S. Postal Service.
16. Governing Law: This Agreement shall be governed by and construed in accordance with the laws of the State of New Jersey.
17. Benefit of Agreement: This Agreement shall enure to the benefit of and be binding upon the heirs, executives, administrators and legal personal representatives of Carota and to and upon the successors and assigns of the Corporation, respectively.
18. Entire Agreement: This Agreement constitutes the entire agreement between the parties hereto with respect to the terms and conditions of employment of Carota and cancels and supersedes any prior understandings and agreements between the parties to this Agreement;provided, however, that the Confidentiality Agreement dated February 11, 2000 shall remain in full force and effect. There are no representations, warranties, forms, conditions, undertakings or collateral agreements expressed, implied or statutory between the parties hereto other than as expressly set forth in this Agreement.
19. Severability: Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision of any other jurisdiction but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.
20. Amendments and Waivers: Any provision of this Agreement may be amended or waived only with prior written consent of the Corporation and Carota.
IN WITNESS WHEREOF, the parties have duly executed this Agreement.
ATTEST: | DUSA PHARMACEUTICALS, INC. | ||
|
| ||
|
| ||
/s/ Susan B. Tennent |
| By: | /s/ Ronald L. Carroll |
|
| Ronald L. Carroll, Executive VP and COO | |
|
|
| |
WITNESS: |
| ||
|
| ||
/s/ Scott Lundahl |
| /s/ Mark Carota | |
| Mark Carota |